Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton

Alanna M. Dubrovsky, Mie Jin Lim, Nancy E. Lane

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Osteoporosis in rheumatic diseases is a very well-known complication. Systemic inflammation results in both generalized and localized bone loss and erosions. Recently, increased knowledge of inflammatory process in rheumatic diseases has resulted in the development of potent inhibitors of the cytokines, the biologic DMARDs. These treatments reduce systemic inflammation and have some effect on the generalized and localized bone loss. Progression of bone erosion was slowed by TNF, IL-6 and IL-1 inhibitors, a JAK inhibitor, a CTLA4 agonist, and rituximab. Effects on bone mineral density varied between the biological DMARDs. Medications that are approved for the treatment of osteoporosis have been evaluated to prevent bone loss in rheumatic disease patients, including denosumab, cathepsin K, bisphosphonates, anti-sclerostin antibodies and parathyroid hormone (hPTH 1–34), and have some efficacy in both the prevention of systemic bone loss and reducing localized bone erosions. This article reviews the effects of biologic DMARDs on bone mass and erosions in patients with rheumatic diseases and trials of anti-osteoporotic medications in animal models and patients with rheumatic diseases.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalCalcified Tissue International
StateAccepted/In press - Feb 22 2018


  • Ankylosing spondylitis
  • Anti-osteoporotic medication
  • Anti-rheumatic drug
  • Bone loss
  • Osteoporosis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology


Dive into the research topics of 'Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton'. Together they form a unique fingerprint.

Cite this